Compounds that remain of potential interest because their scores were above either R-naproxen or R-ketorolac and include cilomilast, R-flunoxaprofen, tiagabine, levocabastine, methallenestril, mitiglinide, cicloxilic acid, ecabet, S-ibuprofen, R-ibuprofen and S-naproxen.